The Telehealth Graveyard: GLP-1 Providers That Shut Down in 2025–2026

The compounded GLP-1 telehealth gold rush of 2022–2024 produced hundreds of platforms. The industry correction of 2024–2026 closed many of them. Here's our running record of the notable shutdowns — who, when, why, and what patients on those platforms experienced.

This is not a complete list. New closures happen monthly, and some platforms wind down quietly without public announcement. What follows is a representative snapshot of the patterns, drawn from public reporting, FDA warning letters, state board actions, and patient-facing shutdown notices.

The macro pattern

Shutdowns clustered around four catalysts:

1. FDA shortage list shifts (October 2024 – Feb 2025). When semaglutide and tirzepatide came off the shortage list, the federal basis for compounding became narrower. Platforms that had built their entire business on compounded versions of brand-name drugs faced existential questions.
2. FDA warning letters (2024–2025). The FDA issued coordinated warning letters targeting deceptive marketing, "FDA-approved" claims on compounded products, and inadequate clinical protocols. Some recipients folded.
3. State pharmacy board actions. Several state boards revoked or declined to renew non-resident pharmacy permits, functionally cutting platforms off from major markets.
4. VC funding contraction. Many telehealth platforms were burning cash for growth. As the category cooled and compliance costs rose, follow-on funding dried up. Platforms without a path to profitability exited.

The categories of shutdowns

Category A: Regulatory-triggered

Platforms that shut down following an FDA warning letter, state board action, or similar enforcement event. These shutdowns are usually abrupt — the enforcement action makes continued operation legally or financially untenable within days. Patients on these platforms often had the shortest notice and the most disruption.

Category B: Funding-triggered

Platforms that ran out of money. Sometimes these gave 30–60 days notice and ran orderly wind-downs. Sometimes they announced on a Friday and closed by Monday. Depended heavily on the founders' ethical posture and the bankruptcy counsel's advice.

Category C: Acquisition-masked closure

Platforms that were "acquired" but whose acquisition was essentially a wind-down. The acquiring entity took a customer list and some IP; patients were migrated to a different platform (sometimes without clear notice) or simply told "you need to re-sign-up elsewhere."

Category D: Quiet disappearance

Smaller platforms that stopped taking new patients, stopped shipping, and never formally announced a closure. Patients figured it out through ghosted support channels. These are the hardest to track because there's no news article and no final shareholder letter — just a site that slowly stops working.

Representative shutdown stories

Without naming specific platforms that may still be the subject of legal action, these archetypes showed up repeatedly in 2024–2025:

The "lost its pharmacy" shutdown

A platform's exclusive 503A pharmacy loses its state license or FDA standing. The platform can't pivot to a new pharmacy fast enough. Shipments stop. Platform tries to find a replacement, runs out of cash while scrambling, shuts down. Patients on that platform received a mix of partial refunds, no refunds, and, in several cases, abandoned mid-titration.

The "FDA letter day" shutdown

A platform receives a warning letter in a public FDA posting. Within hours, Google Ads and Facebook Ads accounts are suspended (advertisers pulled for the warning letter). Within days, the platform's customer acquisition engine is dead. Within weeks, without new customer revenue to offset operating costs, the platform closes.

The "compounding exit" shutdown

Following the FDA's shortage list changes, a platform decides compounding is no longer sustainable and announces a transition to brand-name-only. Most customers can't afford brand-name pricing. Customer base collapses by 80% in a month. Platform fails to find financial footing on the smaller customer base and closes.

The "class action" shutdown

A platform becomes the subject of a class action lawsuit alleging a practice-related claim (misleading marketing, inadequate medical oversight, contaminated product). Insurance covers part; legal costs exceed cash reserves; platform files Chapter 7.

What customers consistently reported

Patterns from patients who went through shutdowns:

• Inadequate notice. Most platforms gave less than 30 days, several gave less than 7, a few gave zero.
• Partial or no refunds on unused prepaid balances.
• Lost medical records without active intervention to recover them.
• Support black-hole. Once the shutdown is announced, support response rates drop dramatically.
• Surprise final charges — in some cases, platforms continued processing monthly charges for days or weeks after shutdown. Chargebacks required.
• Re-intake pain at new platforms. Starting over was annoying but solvable. Most patients ended up on a new platform within 1–3 weeks and continued treatment without clinical disruption.

Who did it well

The minority of shutdowns that went smoothly shared traits:

• Early communication. 60–90 days notice, repeated reminders.
• Record-transfer support. A dedicated process to help patients download records and transfer prescriptions.
• Pharmacy partnership for continuity. Arrangements with the pharmacy to continue serving patients under a new platform or directly.
• Prorated refunds on prepaid balances.
• Referral partnerships with other platforms to simplify the transition.

These are the platforms we mention positively in our coverage — even in shutdown, they behaved like real healthcare operations. That's rare.

How to check if a specific platform is still alive

1. Visit the site. Does the main page load? Does the sign-up flow still work?
2. Check the Wayback Machine to see when the site's content was last meaningfully updated.
3. Check their social media. When was the last post? A silent Twitter or Instagram account for six months is a signal.
4. Check Trustpilot and Reddit for recent reviews. Are customers still receiving shipments? Are complaints about non-delivery piling up?
5. Search state corporation records. Is the entity still in good standing?
6. Search for legal filings. PACER (federal courts) and state court records reveal litigation patterns.

What this means for current platform selection

A platform's history of navigating regulatory storms tells you something about its likely future. Platforms that took FDA warning letters seriously and adjusted survived; platforms that ignored them mostly didn't. Platforms with pharmacy diversity survived; platforms dependent on a single vendor were more fragile.

If you're choosing a platform now, look for:

• 3+ years of continuous operation.
• No active FDA warning letters.
• Multiple pharmacy partners or a demonstrated ability to switch pharmacies.
• Transparent ownership and governance.
• Reasonable financial footing (if public signals are available).

These aren't guarantees. But they significantly raise the odds that the platform you pick this year is still your platform next year.